MYC and lymphedema: The MYC gene is a potent oncogene that is amplified in various clinicopathologic subdivisions of angiosarcoma, including secondary (postirradiation and lymphedema-associated) and a subset of primary angiosarcomas (breast, skin, and bone) [15–19]. MYC amplification status has not yet been described in the unusual setting of AVG-associated angiosarcoma; we therefore report MYC amplification status in one such case.